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Active disease 69 (51%) 68 (50%) NR
Recipient/Donor CMV serostatus
R+/D+ 66 (48%) 68 (50%)
R-/D+ or R+/D- 66 (48%) 63 (46%)
R-/D- 4 (3%) 5 (4%) 0.5
Diagnosis
Acute Leukemia 96 (70%) 96 (70%)
Chronic Leukemia 18 (13%) 18 (13%)
Other 22 (17%) 22 (17%) NR
Regimn Intensity *†
Myeloablative 87 (64%) 95 (70%)
Reduced-Intensity 26 (19%) 21 (15%)
Non-Myeloablative 23 (17%) 20 (15%) 0.6
Donor Type
Matched related 55 (40%) 55 (40%)
Matched unrelated 72 (54%) 72 (54%)
1 Antigen mismatched unrelated 3 (2%) 3 (2%)
Haploidentical 5 (4%) 5 (4%) NR
CMV reactivation 56 (41%) 63 (46%) 0.4
Median days to CMV reactivation 26 (range 0-85) 34 (range 2-97) 0.008
CMV disease 1 (0.7%) 5 (4%) 0.1
Day 100 Survival 91% 90% 0.8*Pasquini MC, Wang Z. Current use and outcome of hematopoietic
stem cell transplantation: Part I CIBMTR summary slides, 2009. CIBMTR
Newsletter (serial online), 2009; (15)1:7-11.
†Bacigalupo A, et al. Defining the Intensity of Conditioning Regimens:
Working Definitions. Biol Blood Marrow Transplant 2009; 15: 1628-1633.
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EXTENDED USE OF APREPITANT IN PEDIATRIC PATIENTS
Williams, D.1, Rohatgi, R.1, Seaton, A.2, Makonnen, T.3 1Children’s
National Medical Center, Washington, DC; 2University of Maryland;
3Virginia Commonwealth University
Purpose:This will report a single center experience of safety and ef-
ficacy of aprepitant used for treatment of nausea and vomiting in pe-
diatric stem cell transplant patients, used for greater than 4 days.
Background: Aprepitant is a nuerokinin-1 receptor antagonist that is
FDAapproved topreventnausea andvomitingwithmoderate tohighly
emetogentic chemotherapy. Aprepitant is utlized in combination with
standard antiemtic therapy for a3daydosing schedule in adult patients.
This is a case series inwhichpediatric stemcell transplantpatientswere
prescribed aprepitant for the treatment of nausea and vomiting.
Methods: This is a retrospective review of patient charts and data.
Patients prescribed aprepitant fore extended dosing at Children’s
National Medical Center between the dates of January 1, 2009 and
December 31, 2010 were included.
Inclusion Criteria: Aprepitant prescription for greater than 4 days
Age between 1 year and 17.9 years at the initiation of aprepitant
therapy
Results: Six patient therapy encounters were observed. Patient ages
ranged from 2 years to 16 years of age at the time of therapy. The
duration of aprepitant usage ranged from 5 to 12 days. The doses
of aprepitant ranged from 45mg per body surface area daily to
70mg per body surface area daily. Five out of six (83%) patient en-
counters demonstrated an improvement of emesis with the additionrage Number
mesis During
pitant Therapy
0
0.16
1.6
0.16
0.22
0.25of aprepitant, both during aprepitant therapy and for 72 hours fol-
lowing the discontinuation of aprepitant. (See Table). The number
of rescue antiemetics required did not differ with the addition of
aprepitant. There were no adverse events attributed to aprepitant
usage.
Conclusion: In a single center experience, aprepitant therapy is effec-
tive at decreasing episodes of emesis during therapy and the time pe-
riod up to 72 hours after aprepitant discontinuation, in pediatric
stem cell transplant patients. Use of aprepitant therapy for greater
than three days is not associated with any significant adverse events.
Variations in patient age and standardized dosing based on body sur-
face area need to be further investigated and developed. Additional
larger studies are warranted to determine the most appropriate dosing
scheme based on pediatric developmental pharmacokinetic principles.
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DOSING OF BUSULFAN IN OVERWEIGHT AND OBESE PATIENTS
COMPARED TO NORMALWEIGHT PATIENTS UNDERGOING ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION (alloHSCT)
Tkacz Brown, V.1, Zahurak, M.2, Hatfield Seung, A.1, Rosner, G.2,
Jones, R.J.2, Luznik, L.2, Lombardi Thomas, L.1 1The Johns Hopkins
Hospital, Baltimore, MD; 2The Sidney Kimmel Comprehensive Cancer
Center at The Johns Hopkins Hospital and University, Baltimore, MD
Busulfan has a narrow therapeutic index, making dosing in obesity
a therapeutic dilemma. The busulfan pharmacokinetic (PK) profile is
related to many variables including body size. By normalizing dosing
tobody size, variability in clearance is reduced.The difficulty is the se-
lection of an appropriatemeasure of body size for normalization. The
objectives of this study were to determine if busulfan dosed on ideal
body weight (IBW) in overweight patients (BMI $ 25 kg/m2) leads
to differences in the PK parameter area under concentration-versus-
time curve (AUC) for the first dose and dosing adjustments compared
tonormalweight patients (BMI\25 kg/m2). Secondary objectives in-
clude comparison of transplant outcomes including sinusoidal ob-
struction syndrome (SOS), non-relapse mortality (NRM), event-free
survival (EFS), and overall survival (OS). A retrospective chart review
included 131 patients with hematologic malignancies, 69 of whom
were not in remission, who received an alloHSCT with our busul-
fan/cyclophosphamide preparative regimen and post-transplant cy-
clophosphamide alone as GVHD prophylaxis. Oral or intravenous
busulfan was administered to 72 and 59 patients, respectively, with
routine first dose PK assessment performed with a goal AUC/dose
of 800 – 1400 mMol-min/L. Themajority of the population was over-
weight (67%) and had similar characteristics, with the exception of
a higher portion of males in the overweight group (37% vs. 58%;
p 5 0.026). The median first dose busulfan AUC was 1153 mMol-
min/L (range: 659-1805 mMol-min/L) in the normal weight patients
and 915 mMol-min/L (range: 482-1875 mMol-min/L) in the over-
weight patients (p 5 0.0001); this did not translate into a difference
in dose adjustments at first assessment (p 5 0.522). Ten cases of
SOS were observed with a trend to higher incidence in the normal
weight patients (12% vs. 6%; p 5 0.30). The two year EFS and OS
were improved in overweight patients EFS: 35% (95% CI: 21, 49%)
vs 40% (95% CI: 30, 51%) and OS: 42% (95% CI: 27, 57%) vs
56% (95% CI: 44, 66%), but these differences were not significant
(EFS p5 0.37 and OS p5 0.26). Two year NRMwas lower in over-
weight patients NRM: 23% (95% CI: 12, 37%) vs 12% (95% CI: 6,
19%)p5 0.18.These results demonstrate thatwhenbusulfan is dosed
on IBW, overweight patients may have a lower initial busulfan AUC
than normal weight patients, but these pharmacokinetic differences
may not translate into differences in clinical outcomes.Average Number
of Emesis after
Aprepitant Therapy*
Aprepitant Daily
Dosage (mg/BSA) Patient Age (Years)
1 70 13
0.66 45 16
0 50 3
2 63 3
0 63 3
0 63 4
